Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$1.16MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- D. Lynn Kirkpatrick
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 9
- Beta
- 0.98
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -82.32
Financials
Revenue
$1.16M+35.0%Net Income
$-2.57MEBITDA
$-2.58MFree Cash Flow
$-1.96MEPS (diluted)
$-0.20Shares Outstanding (diluted)
13.04M+117.8%Operating Expenses
$3.74MCash & Debt
$676.7KReturn of Capital
$0.00Revenue by Segment (annual)
$5.07MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-10.18M | $-3.98 |
| 2024 | $0.00 | $-7.99M | $-4.57 |
| 2023 | $0.00 | $-10.61M | $-4.69 |
| 2022 | $0.00 | $-24.17M | $-139.44 |
| 2021 | $0.00 | $-29.08M | $-355.68 |
| 2020 | $0.00 | $56.8K | $0.56 |
| 2019 | $1.76M | $-10.10M | $-1.66 |
| 2018 | $0.00 | $-1.34M | $-0.22 |
| 2017 | $0.00 | $-31.2K | $-0.01 |
Valuation
ENSChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
73-26.67%Social Signal Score
Mentions (7)
- Newsaccessnewswire.com·12d ago·Negative
…r review marks critical step towards initiating a Phase 2 Study with CY200 ~ SAN DIEGO, CA / ACCESS Newswire / September 24, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced the submission of the protocol for a Phase 2a clinical study of CY200, the Company's newest drug candidate from …
View source ↗ - Newsaccessnewswire.com·21d ago·Negative
… at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation SAN DIEGO, CA / ACCESS Newswire / September 15, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), hosted a symposium at PainWeek 2026. The Symposium was attended by more than 320 pain management professionals.
View source ↗ - Newsaccessnewswire.com·22d ago·Negative
… Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs SAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced that Richard Langford, Chief Medical Officer of Cy Biopharma, has been selected to present in person at the U.S. …
View source ↗ - Newsaccessnewswire.com·34d ago·Neutral
…ce Biosciences Announces Upcoming Conference and Industry Event Participation SAN DIEGO, CA / ACCESS Newswire / September 2, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced its participation in the following upcoming investors conferences and industry events. 2026 Cantor Global Healthc…
View source ↗ - Newsaccessnewswire.com·36d ago·Neutral
…Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~ SAN DIEGO, CA / ACCESS Newswire / August 31, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, and advancing next-generation pain and central nervous system therapeutics designed to reduce abuse and overdose risk, today announced completion of enrollment in the f…
View source ↗ - Newsseekingalpha.com·48d ago·Neutral
Ensysce Biosciences, Inc. (ENSC) Discusses Acquisition of Cy Biopharma and Private Placement Financing Prepared Remarks Transcript Ensysce Biosciences, Inc. (ENSC) Discusses Acquisition of Cy Biopharma and Private Placement Financing Prepared Remarks Transcript
View source ↗ - Newsaccessnewswire.com·53d ago·Neutral
…y to host a Corporate Update Call on Tuesday, August 18, 2026, at 11:00 a.m. ET SAN DIEGO, CA / ACCESS Newswire / August 13, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, today reported financial and operational results for the second quarter ended June 30, 2026.
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-0.19 per share
Typical surprise +22.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.20 vs $-0.20beat
- Fri, May 15$-0.52 vs $-0.73beat
- Mon, Mar 30$-0.75 vs $-1.26beat
- Fri, Nov 14$-1.29 vs $-0.85miss
- Wed, Aug 13$-0.79 vs $-1.02beat
- Tue, May 13$-1.39 vs $-3.02beat
Estimates and results for ENSC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ENSC officers and directors.
- Bought
- $11.2m
- Sold
- $8.1m
8 trades
1 trade
- Gower Bob Gbought
- Gower Bob Gbought
- Gower Bob Gbought
- Gower Bob Gbought
- Gower Bob Gbought
- Gower Bob Gbought
- Kirkpatrick Lynnbought
- Morgan Stanleysold
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ENSC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.